Immix Biopharma (IMMX) Research & Development (2021 - 2026)

Immix Biopharma has disclosed Research & Development across 6 years of filings, most recently posting $6.0 million for Q1 2026.

• Research & Development for Q1 2026 came in at $6.0 million, up 202.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.3 million (up 102.25% YoY), and the FY2025 annual result was $16.3 million, up 43.97% from the prior year.
• Research & Development came in at $6.0 million for Q1 2026 at Immix Biopharma, up from $5.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $6.0 million in Q1 2026 to a low of $607751.0 in Q2 2022.
• The 5-year median for Research & Development is $2.2 million (2024), against an average of $2.7 million.
• Across the five-year window, Research & Development surged 24397.17% in 2022 and tumbled 55.68% in 2024, its largest moves.
• Immix Biopharma's Research & Development stood at $2.3 million in 2022, then surged by 37.05% to $3.1 million in 2023, then tumbled by 55.68% to $1.4 million in 2024, then jumped by 316.7% to $5.7 million in 2025, then increased by 4.43% to $6.0 million in 2026.
• The last three Research & Development figures came in at $6.0 million (Q1 2026), $5.7 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.